ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2919

Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis

Krishan Gupta1, Manish Rathi2, Navin Pattanashetti3, Ritambhra Nada4 and Aman Sharma5, 1Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 3Internal Medicine, Junior Resident, Chandigarh, India, 4Histopathology, Professor, Chandigarh, India, 5Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: antiphospholipid syndrome, lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy (TMA) presents with severe clinical manifestations and high mortality. The aim of this study was to assess the spectrum and impact of TMA on the outcomes of LN.

Methods: In this prospective observational study of one and half year duration, clinical and renal histopathological data of 102 patients with biopsy proven LN were noted and in addition evaluatation for antiphospholipid syndrome (APS) as cause of TMA in LN was also carried out. Study subjects were followed up actively for six months and various outcomes were noted. Cases were divided into two groups as LN with TMA and LN without TMA, and various features were compared between two groups.  Renal TMA was defined as intertubular artery and glomerular capillary response including endothelial cell swelling, lumen narrowing or obstruction & thrombi formation by light microscopy. Swelling of glomerular endothelial cells, detachment from glomerular basement membrane and widening of sub-endothelial space were identified by electron microscopy.   Outcomes noted were complete response, partial response, failure and death. 

Results: In the 102 patients with lupus nephritis, 26 patients were diagnosed as co-existing with renal TMA based on strict pathological criteria. Among the 26 patients three patients were found to have concomitant APS (11.5%). As compared to cases without TMA, patients with TMA had significantly higher rates of arthralgia, malar rash, advanced renal injury i.e. serum creatinine >3mg/dl(34.6% Vs 11.84% with P= 0.008), higher percentage of fibrocellular+fibrous crescents (P= 0.018) and tubular atrophy (P= 0.006),. Even though the rates of endocapillary proliferation (73.1% Vs 56.5%), hyaline thrombhi(19.2% Vs 7.9%), and glomerular sclerosis(46.2% Vs 30.3%) were higher in TMA group compared to cases without TMA, but failed achieve statistical significance.. Patients of Lupus nephritis with TMA had poorer outcomes i.e higher rates of failure to treatment(P=0.011) and lower rates of complete response(P=0.031) compared to non TMA group. Renal TMA group is significantly associated with 7.26 times more likely poor outcomes than non TMA group(Odds ratio7.262, 95% confidence interval:1.585 to 31.303, P= 0.008).

Conclusion: Presence of TMA in lupus nephritis is associated with adverse clinicopathological presentation and poorer outcome.


Disclosure: K. Gupta, None; M. Rathi, None; N. Pattanashetti, None; R. Nada, None; A. Sharma, None.

To cite this abstract in AMA style:

Gupta K, Rathi M, Pattanashetti N, Nada R, Sharma A. Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/effect-of-thrombotic-microangiopathy-on-clinical-outcomes-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-thrombotic-microangiopathy-on-clinical-outcomes-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology